Bohlin Garen G's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Sep 12, 2023
- Accession no.
- 0000950170-23-047712
- Filed
- Sep 12, 2023
- Trade date
- Sep 12, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $50.2K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bohlin Garen GCIK 0001254705 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Common Stock | PPurchaseAcquired | +41,140 | $1.22F1 | +$50,190.8 | 45,140 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.1935 to $1.24, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price..
Referenced by the price of 1 transaction in Table I.